A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Impulsive aggression (IA) is linked to various neuropsychiatric disorders but lacks a distinct diagnostic or treatment category.
• Current treatments for maladaptive aggression, including IA, are often insufficient and lack FDA-approved agents specifically for IA.
• This necessitates a more refined approach to drug categorization and treatment for IA.

Purpose of the Study:

• To propose the establishment of a new drug class: anti-maladaptive aggression agents.
• To streamline the treatment approach for impulsive aggression (IA) by unifying existing therapies.
• To review SPN-810 (extended-release molindone) as a potential candidate for this new drug class, specifically within a subgroup of IA modulators.

Main Methods:

• Literature review and analysis of existing pharmacotherapies for maladaptive aggression.
• Examination of the potential classification of SPN-810 within a proposed anti-maladaptive aggression agent class.
• Focus on IA as a key example for demonstrating the utility of new drug categorization.

Main Results:

• Current drug categorization is inadequate for patients with impulsive aggression (IA).
• A new class of anti-maladaptive aggression agents is proposed to unify and improve treatment.
• SPN-810 shows potential as a candidate for this new class, particularly for IA in children with ADHD.

Conclusions:

• Establishing a distinct class of anti-maladaptive aggression agents is crucial for improving IA treatment.
• More precise drug categorization will enhance the identification and therapeutic strategies for maladaptive aggression and IA.
• SPN-810 represents a promising investigational pharmacotherapy that could fit within this proposed new drug class.